Category:

Novartis reported $4.1 billion (3.8 billion euros) in income for the first half of the year, down 20 percent, due largely to a stronger dollar.

Institute for Clinical and Economic Review …launched a program to transform the way new drugs are evaluated and priced…. will produce public reports on new drugs… include a full analysis of a drug's comparative effectiveness, cost-effectiveness, and potential budget impact…Calculate... a value-based price benchmark anchored to the real benefits the drug brings to patients.

When it comes to electric health records (EHR), many docs are more frustrated than ever. "They have so much potential to improve healthcare, improve quality, improve our efficiency, improve patient engagement, and yet that's not the current state of reality,"… "Our experience as physicians is often falling far short of the promise…"

Boston’s doctors have done it again….U.S. News & World Report assessed about 5,000 hospitals to determine the “Best Hospitals” for 2015-2016, and Massachusetts General Hospital came out on top….runner-up the Mayo Clinic and Johns Hopkins Hospital at No. 3.

federal appeals court has ruled that Novartis can begin selling its lower-cost copy of an Amgen Inc. drug (Zarxio biosimilar to Neupogen)....rejecting a bid to further delay the launch of the knock-off biotech medication.

Amgen Inc. won approval in the European Union for its drug Repatha, the first regulatory clearance for a new class of powerful cholesterol-lowering drugs… for patients with uncontrolled cholesterol who require additional intensive reduction of low density lipoprotein...

Abbott Laboratories Inc reported a slightly better-than-expected quarterly profit, helped by higher sales of its branded generics...pharmaceutical products business,..rose 31.3 percent to $977 million,..

Joe Jimenez said the consolidation spree among U.S. health insurers is making it harder… to increase prices in a market that has for years been a primary driver of growth for the pharmaceutical industry.. "..the pricing environment is more difficult," "With a consolidated payer base as well as consolidated providers, you have to assume going forward that price increases in the U.S. are going to be quite limited."

FDA sent a warning letter to Vista Pharmaceuticals, which is based in India, for not paying Generic Drug User Fee Act fees on time. This is the fourth time this month.. Failure to pay... fees is an international problem. This month alone, companies in India, the U.S. and China were fined for failure to pay in a timely manner.

adoption of robots to help in minimally invasive surgery grows, so, too, do technical difficulties and complications...researchers indicated that...rates are high because of procedure complexity, infrequent use of robotic devices and less expertise...